Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study by Li-Han Hsu et al.
RESEARCH ARTICLE Open Access
Pleural fluid osteopontin, vascular
endothelial growth factor, and urokinase-
type plasminogen activator levels as
predictors of pleurodesis outcome and
prognosticators in patients with malignant
pleural effusion: a prospective cohort study
Li-Han Hsu1,2,3, Pei-Chi Hsu4, Tien-Ling Liao4, An-Chen Feng5, Nei-Min Chu6 and Shu-Huei Kao1,4*
Abstract
Background: Rapidly growing cancer cells secrete growth-promoting polypeptides and have increased proteolytic
activity, contributing to tumor progression and metastasis. Their presentation in malignant pleural effusion (MPE)
and their predictive value for the outcome of pleurodesis and survival were studied.
Methods: Between February 2011 and March 2012, MPE samples were prospectively collected from 61 patients.
Twenty-five patients with non-malignant pleural effusion in the same period were included as controls. Pleural fluid
osteopontin (OPN), vascular endothelial growth factor (VEGF), and urokinase-type plasminogen activator (uPA)
concentrations were measured.
Results: Patients with MPE had higher pleural fluid OPN, VEGF, and uPA concentrations than those with non-
malignant pleural effusion, but only differences in VEGF were statistically significant (p = 0.045). Patients with distant
metastases had significantly elevated pleural fluid VEGF concentrations than those without (p = 0.004). Pleural fluid
OPN, VEGF, and uPA concentrations were positively correlated in most patients. However, there was no significant
difference in pleural fluid OPN, VEGF, and uPA concentrations between patients with successful pleurodesis and
those without. There was also no significant difference in cancer-specific survival between sub-groups with higher
and lower pleural fluid OPN, VEGF, or uPA concentrations. Patients with successful pleurodesis had significantly
longer cancer-specific survival than those without (p = 0.015).
Conclusions: Pleural fluid OPN, VEGF, and uPA concentrations are elevated in MPE but are not satisfactory
predictors of pleurodesis outcome or survival. Patients with higher pleural fluid VEGF concentration have higher risk
of distant metastasis. Evaluating the benefits of therapy targeting the VEGF pathway in these patients warrants
further studies.
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Background
Malignant pleural effusions (MPE) frequently cause re-
spiratory compromise in cancer patients. The character-
istics of malignant pleural fluid vary widely, from free-
flowing to fibrinous and from sero-sanguinous to bloody.
Drainage followed by instillation of sclerosing agents is
often used to prevent pleural fluid accumulation and to
improve the patient’s quality of life [1–3]. However, the
efficacy of this treatment varies and its effect on cancer
survival is uncertain. Rapidly growing cancer cells fre-
quently secrete growth-promoting polypeptides and have
increased proteolytic activity. Several studies indicate
that growth factors have an ability to modulate the ex-
pression of proteolytic enzymes [4]. Osteopontin (OPN),
a small integrin-binding ligand N-linked glycoprotein, is
emerging as an important player in regulating cell sig-
naling that controls tumor progression and metastasis
[5, 6]. Vascular endothelial growth factor (VEGF) can in-
crease vascular permeability and the proliferation and
migration of endothelial cells. Both OPN and VEGF are
involved in the production of urokinase-type plasmino-
gen activator (uPA) and the formation of MPE [7–10].
The balance of plasminogen activator and plasminogen
activator inhibitor (PAI) determines the pro-coagulant
and fibrinolytic activities within the pleural space [11, 12].
Increased intra-pleural fibrinolysis will lead to failure of
pleurodesis [13, 14]. On the other hand, an over-
expression of pro-coagulant activities precipitates fibrin
deposition and results in loculated malignant pleural effu-
sions or trapped lungs [15–19]. The fibrin-generation
process is reported to prohibit tumor cell invasion and
metastasis [20–24].
In this study, pleural fluid OPN, VEGF, and uPA con-
centrations from patients with MPE on its initial pres-
ence were measured and their correlations determined.
Under the hypothesis that higher pleural fluid OPN,
VEGF, and uPA concentrations could be a predictor of
pleurodesis failure or poor prognosis in patients with
MPE, their associations with pleurodesis outcome and
cancer-specific survival were investigated.
Methods
Patients
This prospective study was approved by the Institutional
Review Board of the Sun Yat-Sen Cancer Center and by
the hospital’s Ethics Committee. It was conducted in ac-
cordance with the ethical principles of the Declaration
of Helsinki and guidelines on good clinical practice. All
of the patients provided written informed consent.
Sixty-one consecutive patients who were symptomatic
from MPE on its initial presence were prospectively re-
cruited between February 2011 and March 2012. Their
mean age was 57 years and 45 were women (Table 1).
Of the 61 patients, 32 had lung cancer, 19 had breast
cancer, and four had ovarian cancer, while transitional cell
carcinoma, colon cancer, melanoma, pancreatic cancer,
lymphoma, and unknown primary adenocarcinoma had
one patient each. Forty-four patients had distant metasta-
sis other than MPE (20 with lung cancer, 16 with breast
cancer, 3 with ovarian cancer, and one each with transi-
tional cell carcinoma, colon cancer, melanoma, pancreatic
cancer, and unknown primary adenocarcinoma).
Median survival was 198 days after the presence of
MPE was noted (128 days in lung cancer and 222 days
in breast cancer). Pleural fluid samples were obtained by
standard thoracentesis using size 8–14 Fr self-retaining
intra-pleural catheter (Pigtail drainage tube; Create
Medic, Yokohama, Japan). The MPE was confirmed by
cell block cytology or closed pleural biopsy. The pleural
fluid samples were immediately centrifuged to remove
cells and debris, and then stored at -80 °C for analysis.
Twenty-six patients had good ipsilateral lung re-
expansion when the intra-pleural catheter drainage was
stopped. They were eligible for chemical pleurodesis
with minocycline (Lederle Parenterals, Carolina, Puerto
Rico). Follow-up chest radiographs were obtained at 1,
3, and 6 months after pleurodesis and repeated as
needed. Fifteen (six with breast cancer, six with lung
cancer, and one each with ovarian cancer, lymphoma,
and unknown primary adenocarcinoma) achieved
complete or partial success. Eleven (six with breast can-
cer and five with lung cancer) had failed pleurodesis ac-
cording to the definitions proposed by the American
Thoracic Society and the European Respiratory Society
Consensus Statement [1]. The remaining patients who
were not suitable for pleurodesis because of loculated
pleural effusion or trapped lung were also followed.
Twenty-five patients (15 women; mean age, 64 years)
with non-malignant pleural effusion in the same period
were included as controls. Their etiologies were inde-
terminate lymphocyte predominant exudate (n = 13),
Table 1 Characteristics of patients with malignant pleural
effusion
All Lung cancer Breast cancer Others
Number 61 32 19 10
Agea 57.0±11.8 59.9±12.9 53.6±11.1 55.0±8.5
Sex
Male 16 12 0 4
Female 45 20 19 6
Pre-menopausal 16 7 7 2
Post-menopausal 29 13 12 4
Distant metastasis
Yes 44 20 16 8
No 17 12 3 2
aData are presented as mean ± standard deviation
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para-pneumonia (n = 3), heart failure (n = 3), surgery or
radiotherapy (n = 3), transudates secondary to liver cirrho-
sis or metastasis (n = 2) and pulmonary embolism (n = 1).
All pleural fluid samples were examined with cell block
and confirmed negative for malignancy.
Measurement of pleural fluid OPN, VEGF, uPA, and PAI-1
concentrations
The concentrations of OPN, VEGF, uPA, and PAI-1 in the
supernatants of the pleural fluid samples were measured by
commercially available enzyme-linked immuno-sorbent
assay kits: OPN (TiterZyme® EIA Human Osteopontin En-
zyme Immunometric Assay Kit; Assay Designs, Ann Arbor,
MI, USA), VEGF (Human VEGF Immunoassay kit; Invitro-
gen, Camarillo, CA, USA), uPA (u-PA Activity Assay Kit;
Chemicon, Temecula, CA, USA), and PAI-1 (PAI Activity
Assay Kit; Chemicon). The concentrations of OPN and
uPA were expressed as ng/mL, while the concentrations of
VEGF and PAI-1 were expressed as pg/mL.
Aside from numerical data, the OPN, VEGF, uPA, and
PAI-1 concentrations were also coded as high or low
using median cut-offs. To relate uPA and PAI-1 with
clinical outcome, a binary variable, uPA/PAI-1 was eval-
uated, since previous studies had shown that the com-
bination of both markers provided better risk-group
discrimination than either one alone [24].
Pleural fluid OPN, VEGF, uPA, and PAI-1 concentrations
were compared between patients with MPE and those with
non-malignant pleural effusion and between sub-groups of
MPE patients divided by sex, underlying malignancy, and
presence of distant metastasis. Pre-menopausal status was
associated with more advanced disease and a shorter sur-
vival among never-smoking female patients with lung
adenocarcinoma, implying an estrogen cancer-promoting
effect [25], comparison was also made between the pre-
and post-menopausal women. Linear regression analyses
were performed to measure correlations among pleural
fluid OPN, VEGF, uPA, and PAI-1 concentrations in MPE.
Investigation of the association between pleural fluid
OPN, VEGF, uPA, and PAI-1 concentrations and
pleurodesis outcome and survival
Pleural fluid OPN, VEGF, uPA, and PAI-1 concentra-
tions were compared between patients with successful
pleurodesis and those without. Kaplan-Meier plots and
log-rank tests were used to assess the association be-
tween pleural fluid OPN, VEGF, uPA, and PAI-1 concen-
trations and cancer-specific survival. Log-rank test was
also used to compare cancer-specific survival between
patients with and those without successful pleurodesis.
Statistical analysis
Descriptive statistics of mean, median, standard deviation,
and frequency were used to process the demographic and
laboratory data. Categorical variables were compared
using Chi-square test, while continuous variables were
compared using independent t test. Statistical significance
was set at p < 0.05. All analyses were performed using the
statistical software package SAS, version 9.4 (SAS Insti-
tute; Cary, NC, USA).
Results
Patients with MPE had significantly higher pleural fluid
VEGF concentrations, especially in those with distant
metastases
Patient with MPE had higher pleural fluid OPN (mean,
826.85 ± 161.45 vs. 655.88 ± 84.83 ng/mL; p = 0.578),
VEGF (mean, 3720.72 ± 747.19 vs. 2036.15 ± 317.58 pg/mL;
p = 0.045), and uPA (mean, 52.25 ± 14.60 vs. 28.03 ±
2.96 ng/mL; p = 0.274) concentrations than those with non-
malignant pleural effusion. However, only the difference
in VEGF concentration reached statistical significance.
There was no significant difference in pleural fluid OPN,
VEGF, uPA, and PAI-1 concentrations between different
sub-groups except for those with distant metastases in
addition to MPE. They had significantly higher pleural
fluid VEGF concentrations than those without distant
metastases (mean, 4624.28 ± 990.75 vs. 1382.08 ±
458.78 pg/mL; p = 0.004) (Table 2).
Positive correlations among pleural fluid OPN, VEGF, and
uPA concentrations in patients with MPE
Pleural fluid OPN, VEGF, and uPA concentrations posi-
tively correlated with each other (Table 3). The correlation
coefficient between pleural fluid OPN and VEGF concen-
trations was stronger than that between VEGF and uPA,
and that between OPN and uPA. Pleural fluid uPA and
PAI-1 concentrations were negatively correlated.
In sub-group analysis, the correlation coefficient be-
tween pleural fluid OPN and VEGF concentrations was
stronger in males, post-menopausal females, lung cancer
patients, breast cancer patients, and patients with distant
metastases. The correlation coefficient between pleural
fluid VEGF and uPA concentrations was stronger in
males and pre-menopausal females. The correlation co-
efficient between pleural fluid OPN and uPA concentra-
tion was stronger in males. Pleural fluid uPA and PAI-1
concentrations were negatively correlated across differ-
ent sub-groups.
There were no associations of pleural fluid OPN, VEGF,
uPA and PAI-1 concentrations with pleurodesis outcome
and survival
There was no significant difference in pleural fluid OPN
(mean, 809.53 ± 287.72 vs. 361.54 ± 71.80 ng/mL; p =
0.151), VEGF (mean, 5610.94 ± 2040.61 vs. 3564.96 ±
1044.12 pg/mL; p = 0.383), uPA (mean, 99.04 ± 53.88 vs.
25.80 ± 3.22 ng/mL; p = 0.198), and PAI-1 (mean,
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1099.87 ± 130.85 vs. 1306.31 ± 106.46 pg/mL; p =
0.240) concentrations or uPA/PAI-1 ratio (p = 0.336)
between patients with and those without successful
pleurodesis.
When stratified at the median, there was no signifi-
cant difference in cancer-specific survival between pa-
tients with higher and lower pleural fluid OPN
(median, 128 vs. 138 days; p = 0.773), VEGF (median,
127 vs. 147 days; p = 0.531), uPA (median, 128 vs.
145 days; p = 0.232), and PAI-1 (median, 178 vs.
108 days; p = 0.831) concentrations or uPA/PAI-1 ra-
tio (median, 128 vs. 138 days; p = 0.710). Since pa-
tients with lung cancer and MPE had shorter survival
than those with breast cancer, survival analyses were
also separately done on the lung cancer and breast
cancer sub-group to determine the effect of tumor
heterogeneity.
In the lung cancer sub-group, patients with higher
pleural OPN had shorter cancer-specific survival
(median, 113 vs. 146 days; p = 0.026). There was no
significant difference in cancer-specific survival be-
tween patients with higher and lower pleural fluid
VEGF, uPA, and PAI-1 concentrations or uPA/PAI-1
ratio. In the breast cancer sub-group, there was no
significant difference in cancer-specific survival be-
tween patients with higher and lower pleural fluid
OPN, VEGF, uPA, and PAI-1 concentrations or uPA/
PAI-1 ratio.
Table 2 Pleural fluid OPN, VEGF, uPA, and PAI-1 concentrations in patients with malignant pleural effusion
OPN (ng/mL) p value VEGF(pg/mL) p value uPA(ng/mL) p value PAI-1(pg/mL) p value
All 826.85 ± 161.45 3720.72 ± 747.19 52.25 ± 14.60 1228.42 ± 69.74
Sex 0.666 0.649 0.079 0.788
female 784.84 ± 172.59 3515.24 ± 897.44 61.25 ± 19.40 1236.17 ± 87.96
male 945.01 ± 387.95 4298.61 ± 1356.14 25.84 ± 3.53 1203.24 ± 83.89
Female 0.168 0.905 0.549 0.854
Pre-menopausal 1147.57 ± 381.79 3375.61 ± 1146.41 48.21 ± 17.76 1215.35 ± 115.62
Post-menopausal 564.60 ± 144.27 3600.02 ± 1279.00 68.70 ± 28.92 1249.18 ± 125.16
Pathology 0.497 0.938 0.615 0.788
lung cancer 990.10 ± 273.93 3270.75 ± 866.73 47.47 ± 13.33 1243.12 ± 94.15
breast cancer 752.21 ± 213.94 3163.96 ± 1015.91 37.52 ± 12.82 1203.66 ± 102.48
Distant metastasis 0.720 0.004 0.485 0.855
Yes 790.42 ± 186.64 4624.28 ± 990.75 57.50 ± 19.34 1236.77 ± 88.35
No 921.14 ± 128.15 1382.08 ± 458.78 39.27 ± 17.25 1208.38 ± 110.42
Data are presented as mean ± standard deviation
Table 3 Relationships between pleural fluid OPN, VEGF, uPA, and PAI-1 concentrations in patients with malignant pleural effusion





Pre-menopausal Post-menopausal Yes No
OPN & VEGF
r 0.466 0.750 0.279 −0.105 0.824 0.493 0.709 0.503 0.655
p value <0.001 0.032 0.005 0.088 0.023 0.010 0.029 0.001 0.462
VEGF & uPA
r 0.244 0.894 0.282 0.717 −0.047 0.360 −0.034 0.344 −0.108
p value < 0.001 0.006 < 0.001 0.010 0.002 < 0.001 0.005 < 0.001 0.010
OPN & uPA
r 0.068 0.642 0.054 0.074 −0.009 0.081 0.008 0.145 −0.104
p value < 0.001 0.017 < 0.001 0.011 < 0.001 < 0.001 0.001 < 0.001 0.010
uPA & PAI-1
r −0.682 −0.612 −0.689 −0.808 −0.618 −0.679 −0.717 −0.652 −0.831
p value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
r, correlation coefficient
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Patients with successful pleurodesis had significantly
longer cancer-specific survival than those without (me-
dian, 220 vs. 112 days; p = 0.015) (Fig. 1).
Discussion
Recent research has elucidated the pivotal role of OPN
in regulating cell signaling that controls tumor progres-
sion and metastasis. Enhanced OPN expression has been
noted in the plasma of advanced lung cancer patients
and associated with MPE [26–29]. Moreover, OPN has
been speculated to be involved in the formation of MPE
[30]. On the other hand, VEGF is a mitogen for endothe-
lial cells involved in angiogenesis and is a potent inducer
of vascular permeability. It has also been reported as a
key mediator in pleural fluid formation [9]. Together,
OPN has been reported to up-regulate VEGF through
the Akt activation and the induction of HIF-1α expres-
sion [31]. In the present study, the positively correlated
pleural fluid OPN and VEGF concentrations across
different sub-groups support the assumption that
OPN can induce the release of VEGF and promote
MPE formation [30, 32–34].
The plasminogen activator system consists of plas-
minogen activators (urokinase and tissue-type plas-
minogen activators), their receptors, and their
inhibitors. Plasminogen activators split plasminogen
to plasmin, which can then break down extracellular
matrix components. Thus, OPN-induced cancer cell
migration and invasion requires uPA [35–37], while
VEGF can induce pro-uPA activation on the surface
of endothelial cells. The angiogenic response of endo-
thelial cells initiated by VEGF is accompanied by the
assembly of cell surface-bound proteolytic machinery
as a prerequisite for focal invasion [38, 39]. Stepwise
analysis also identifies uPA as an independent factor
correlated with micro-vessel density [40].
The positively correlated pleural fluid OPN and uPA, and
VEGF and uPA concentrations in patients with MPE pro-
vide clinical evidences of prior laboratory findings. Add-
itional experiments are needed to clarify the sequence of
action of OPN, VEGF, and uPA in the formation of MPE,
which may include quantification of pleural fluid mRNA by
quantitative real-time PCR, immuno-histochemical staining
of freshly isolated pleural cells, measurement of their pro-
duction by cultured cells from pleural fluids, in situ mRNA
hybridization, and zymography to evaluate the spatial and
temporal expression [41–44].
Tumor tissue expression and plasma concentration of
OPN and VEGF have been correlated with advanced
stage and poor survival in most common malignancies,
although a small number of studies have also shown no
correlation [45]. In patients with lung cancer and MPE,
Zhang et al. reported that OPN in pleural effusion was
an independent prognostic factor [46]. Kotyza et al. and
Hooper et al. demonstrated a significant association be-
tween increased pleural fluid VEGF and reduced survival
in malignant pleural effusion [47, 48]. Except for OPN in
the lung cancer sub-group, the present study did not
find any survival difference between sub-groups with
higher and those with lower pleural fluid OPN, VEGF, or
uPA concentrations in the others. The conflicting results
may be attributed to the heterogeneity of the underlying
malignancies, with different expected survival rates,
small number of each cancer sub-group, and different
specimens tested.
Survival analysis was also different across studies.
While some employed the log-rank test applied to
Kaplan Meier curves above and below the cut-off value
Fig. 1 Patients with successful pleurodesis had significantly longer cancer-specific survival than those without
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of each parameter, others used Spearman’s rank correl-
ation. Further validation of the pleural fluid processing,
measurement, and unification of the statistical methods
are necessary. The introduction of chemotherapy or tar-
geted therapy before the presence of MPE also affected
the survival analysis compared to chemotherapy- or tar-
geted therapy-naïve patients with MPE as one of the first
manifestations at diagnosis.
However, compared to OPN or uPA, VEGF is signifi-
cantly higher in patients with MPE than in the controls,
especially in patients with distant metastases in addition
to MPE. The potential relevance of pleural fluid VEGF
concentration in selecting patients undergoing adjuvant
treatment targeting the VEGF pathway is a particularly
interesting area for future research.
Although the uPA concentration is elevated in the
MPE, the more substantially elevated concentrations of
its inhibitors, namely PAI-1 and PAI-2, likely result in
depressed fibrinolytic activity and favor the deposition
and maintenance of intra-pleural fibrin. Pedersen et al.
proposed that PAI-1 served to protect cancer tissue
against the proteolytic degradation that the tumor im-
posed upon the surrounding normal tissue [49, 50]. In
contrast, breast cancer patients with high uPA/PAI-1
ratio in tumor tissue extracts are reported to have in-
creased relapse risk [23, 24]. The failure to counterbal-
ance the exuberant production of uPA characteristic of
tumor cells by the timely production of sufficient PAI-1
by host cells may contribute to neoplastic proliferation
and formation of metastasis. The latter is more consist-
ent with the hypothesis of the present study. However,
there is no association of increased pleural fluid uPA
concentrations or uPA/PAI-1 ratio with lower success
rate of pleurodesis or shorter survival. Such contradict-
ory results may be attributed to the case number of this
study, which may be too small to discern differences and
different specimens tested.
Pleurodesis is traditionally regarded as symptomatic
treatment, with rare mention in literature of its benefit
on survival. Hirata et al. reported that patients with
breast cancer and MPE receiving systemic therapy
following the initial talc pleurodesis had longer survival
than those receiving systemic therapy alone [51].
Recently, Korsic et al. reported that patients who under-
went successful talc pleurodesis had significantly longer
survival than patients in the control group treated with
serial thoracentesis, especially in the groups with breast
cancer and better performance status [52]. Antony et al.
demonstrated a strong apoptotic effect of talc on cells of
malignant mesothelioma in vitro [53]. They also found
that pleural mesothelial cells released great amounts of
endostatin after pleurodesis [54].
Talc alters angiogenic balance in the pleural space
from a biologically active and angiogenic environment to
an angiostatic milieu. However, the above-mentioned
survival benefit does not seem to be limited to talc.
Patients with successful minocycline pleurodesis in this
study also have significantly longer survival than those
with failed pleurodesis (Fig. 1). The fibrin-generation
potential of patients following installation of sclerosing
agent is decisive for pleurodesis outcome and survival.
Successfully induced pleural fibrosis is supposed to
prohibit tumor invasion and metastasis. Recruiting more
patients with MPE in the future may help to confirm
these findings.
To date, this is the first study to prospectively evaluate
the presentations and relationship among pleural fluid
OPN, VEGF, and uPA concentrations in patients with
MPE and examine their association with pleurodesis
outcome and survival. There are several limitations that
need to be overcome, including the small sample size
and heterogeneity of underlying malignancies.
Conclusions
Although elevated in malignant pleural effusion, pleural
fluid OPN, VEGF, and uPA concentrations are neither
satisfactory predictors of pleurodesis outcome or prog-
nosticators from the current study. However, patients
with higher pleural fluid VEGF concentration have a
higher risk of distant metastasis. Further study is re-
quired to evaluate the benefit of this sub-group from
therapy targeting the VEGF pathway.
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